Holen Sie sich die Stockscreener-App
31.37
1.26%
-0.40
Handel nachbörslich:
31.37
Schlusskurs vom Vortag:
$31.77
Offen:
$32.06
24-Stunden-Volumen:
212.12K
Relative Volume:
0.40
Marktkapitalisierung:
$878.26M
Einnahmen:
$17.16M
Nettoeinkommen (Verlust:
$-163.62M
KGV:
-5.1595
EPS:
-6.08
Netto-Cashflow:
$-121.61M
1W Leistung:
+1.39%
1M Leistung:
+37.71%
6M Leistung:
+93.17%
1J Leistung:
-1.97%
1-Tages-Spanne:
$31.18
$32.38
1-Wochen-Bereich:
$29.48
$32.53
52-Wochen-Spanne:
$12.21
$36.54
Anaptysbio Inc Stock (ANAB) Company Profile
Firmenname
Anaptysbio Inc
Sektor
Branche
Telefon
858-362-6295
Adresse
10770 WATERIDGE CIRCLE, SUITE 210, SAN DIEGO, CA
Vergleichen Sie ANAB mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ANAB
Anaptysbio Inc
|
31.37 | 888.70M | 17.16M | -163.62M | -121.61M | -6.08 |
|
VRTX
Vertex Pharmaceuticals Inc
|
407.79 | 106.37B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
460.46 | 59.90B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
564.63 | 60.40B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
796.92 | 49.56B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
320.10 | 36.88B | 4.56B | -176.77M | 225.30M | -1.7177 |
Anaptysbio Inc Stock (ANAB) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-06-04 | Hochstufung | H.C. Wainwright | Neutral → Buy |
| 2025-02-04 | Eingeleitet | Wolfe Research | Outperform |
| 2024-12-11 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2024-12-02 | Herabstufung | BTIG Research | Buy → Neutral |
| 2024-07-22 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-07-19 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2024-04-16 | Eingeleitet | Leerink Partners | Outperform |
| 2024-04-11 | Eingeleitet | Wells Fargo | Overweight |
| 2024-03-12 | Hochstufung | Wedbush | Neutral → Outperform |
| 2024-02-26 | Eingeleitet | BTIG Research | Buy |
| 2024-02-21 | Eingeleitet | Stifel | Buy |
| 2024-02-16 | Eingeleitet | Piper Sandler | Overweight |
| 2023-05-22 | Hochstufung | JP Morgan | Underweight → Neutral |
| 2023-05-18 | Eingeleitet | TD Cowen | Outperform |
| 2023-01-06 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2022-11-01 | Hochstufung | Guggenheim | Neutral → Buy |
| 2022-09-19 | Fortgesetzt | H.C. Wainwright | Buy |
| 2022-09-13 | Herabstufung | Truist | Buy → Hold |
| 2022-09-01 | Eingeleitet | Raymond James | Outperform |
| 2022-03-22 | Herabstufung | Guggenheim | Buy → Neutral |
| 2021-06-22 | Eingeleitet | H.C. Wainwright | Buy |
| 2021-05-21 | Eingeleitet | UBS | Neutral |
| 2021-03-16 | Hochstufung | Truist | Hold → Buy |
| 2021-03-09 | Herabstufung | Wedbush | Outperform → Neutral |
| 2021-03-08 | Herabstufung | JP Morgan | Overweight → Underweight |
| 2021-02-11 | Hochstufung | JP Morgan | Underweight → Overweight |
| 2020-10-27 | Hochstufung | Wedbush | Neutral → Outperform |
| 2020-10-14 | Hochstufung | Guggenheim | Neutral → Buy |
| 2019-11-08 | Herabstufung | JP Morgan | Overweight → Underweight |
| 2019-11-08 | Herabstufung | Jefferies | Buy → Hold |
| 2019-11-08 | Herabstufung | SunTrust | Buy → Hold |
| 2019-11-08 | Herabstufung | Wedbush | Outperform → Neutral |
| 2019-06-21 | Herabstufung | Credit Suisse | Outperform → Neutral |
| 2019-06-21 | Herabstufung | Stifel | Buy → Hold |
| 2018-12-20 | Eingeleitet | H.C. Wainwright | Buy |
| 2018-11-21 | Eingeleitet | JP Morgan | Overweight |
| 2018-07-19 | Eingeleitet | Credit Suisse | Outperform |
| 2018-04-04 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2018-03-27 | Bestätigt | Stifel | Buy |
| 2018-03-06 | Bestätigt | Stifel | Buy |
| 2018-02-15 | Bestätigt | SunTrust | Buy |
| 2018-01-23 | Bestätigt | Credit Suisse | Outperform |
| 2017-11-15 | Eingeleitet | SunTrust | Buy |
| 2017-11-09 | Eingeleitet | Jefferies | Buy |
| 2017-10-11 | Bestätigt | RBC Capital Mkts | Outperform |
| 2017-09-15 | Eingeleitet | RBC Capital Mkts | Outperform |
Alle ansehen
Anaptysbio Inc Aktie (ANAB) Neueste Nachrichten
AnaptysBio Inc. stock prediction for this weekQuarterly Growth Report & AI Driven Stock Reports - newser.com
Can AnaptysBio Inc. (AN6) stock resist broad market declinesWeekly Stock Recap & Reliable Intraday Trade Alerts - newser.com
Will AnaptysBio Inc. (AN6) stock outperform benchmarks2025 Top Decliners & Free Verified High Yield Trade Plans - newser.com
Should you wait for a breakout in AnaptysBio Inc.July 2025 Weekly Recap & Technical Buy Zone Confirmations - newser.com
Why AnaptysBio Inc. stock could outperform in 20252025 Institutional Moves & AI Powered Market Trend Analysis - newser.com
AnaptysBio's (ANAB) "Sell (D-)" Rating Reaffirmed at Weiss Ratings - MarketBeat
AnaptysBio, Inc. Experiences Revision in Stock Evaluation Amid Market Dynamics - Markets Mojo
AnaptysBio, Inc. (NASDAQ:ANAB) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
HighMark Wealth Management LLC Raises Stock Position in AnaptysBio, Inc. $ANAB - MarketBeat
Leerink Partnrs Decreases Earnings Estimates for AnaptysBio - MarketBeat
Custom strategy builders for tracking AnaptysBio Inc.Market Sentiment Report & Growth Focused Stock Reports - newser.com
Is AnaptysBio Inc. reversing from oversold territoryWeekly Trade Review & Daily Chart Pattern Signals - newser.com
Applying sector rotation models to AnaptysBio Inc.2025 Bull vs Bear & Reliable Price Breakout Signals - newser.com
Chart overlay techniques for tracking AnaptysBio Inc.July 2025 Short Interest & Safe Capital Growth Stock Tips - newser.com
Is AnaptysBio Inc. (AN6) stock good for long term investingEarnings Miss & Breakout Confirmation Alerts - newser.com
AnaptysBio (NASDAQ:ANAB) Stock Price Down 5.9%Time to Sell? - MarketBeat
HC Wainwright Analysts Cut Earnings Estimates for AnaptysBio - MarketBeat
Biggest stock movers today: UUUU, FLY, and more - MSN
AnaptysBio (NASDAQ:ANAB) Trading 8.9% Higher After Analyst Upgrade - Defense World
AnaptysBio, Inc. Experiences Revision in Stock Evaluation Amid Market Volatility - Markets Mojo
AnaptysBio (NASDAQ:ANAB) Shares Up 8.9% on Analyst Upgrade - MarketBeat
AnaptysBio Charts Path To Split Into Two Public Companies By 2026 - Sahm
AnaptysBio (NASDAQ:ANAB) Price Target Raised to $59.00 at HC Wainwright - Defense World
AnaptysBio (NASDAQ:ANAB) Shares Gap Up on Analyst Upgrade - Defense World
A house dividing: Anaptysbio wants separate pipeline, royalty firms - BioWorld MedTech
AnaptysBio Announces Business Separation Plans - The Globe and Mail
AnaptysBio Stock Rise: Analyzing Latest Developments - timothysykes.com
AnaptysBio Split Will Establish Separate Royalty And Biopharma Firms - insights.citeline.com
Biggest stock movers Tuesday: WOLF, UUUU, FLY, and more - MSN
AnaptysBio climbs after Leernik raises PT on investor-friendly spinoff plans - TradingView
AnaptysBio Stock Gets A Price Target Hike After Announcing Plan To Separate Royalty, Biopharma Businesses – Check Out The New Level - Stocktwits
J.P. Morgan Maintains AnaptysBio(ANAB.US) With Buy Rating - 富途牛牛
AnaptysBio rises on plans to split company - The Pharma Letter
AnaptysBio stock price target raised to $37 from $32 at Leerink Partners - Investing.com Canada
AnaptysBio's Split Announcement Seems 'Awkward' Amid Clinical Activities, Truist Securities Says - MarketScreener
United Natural Foods Posts Upbeat Results, Joins AnaptysBio, Semtech, UiPath And Other Big Stocks Moving Higher On Tuesday - Benzinga
AnaptysBio (NASDAQ:ANAB) Shares Gap Up Following Analyst Upgrade - MarketBeat
Guggenheim Maintains AnaptysBio(ANAB.US) With Buy Rating, Maintains Target Price $90 - 富途牛牛
Wedbush Reiterates Outperform Rating on AnaptysBio (ANAB) with $45 Target | ANAB Stock News - GuruFocus
A Quick Look at Today's Ratings for AnaptysBio(ANAB.US), With a Forecast Between $57 to $59 - 富途牛牛
ANAB: HC Wainwright & Co. Raises Price Target to $59, Maintains Buy Rating | ANAB Stock News - GuruFocus
Wedbush Reiterates "Outperform" Rating for AnaptysBio (NASDAQ:ANAB) - MarketBeat
AnaptysBio stock price target raised to $59 from $38 at H.C. Wainwright - Investing.com Canada
HC Wainwright & Co. Maintains AnaptysBio (ANAB) Buy Recommendation - Nasdaq
AnaptysBio stock rises on plans to separate royalty business from biopharma - Investing.com Canada
AnaptysBio (ANAB) Rises on Strategic Split into Two Entities - GuruFocus
Biggest stock movers today: UUUU, FLY, and more (NYSE:UUUU) - Seeking Alpha
Finanzdaten der Anaptysbio Inc-Aktie (ANAB)
Umsatz
Nettogewinn
Free Cashflow
ENV
Anaptysbio Inc-Aktie (ANAB) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| LOUMEAU ERIC J | CHIEF LEGAL OFFICER |
Sep 30 '25 |
Sale |
29.00 |
8,240 |
238,960 |
9,088 |
5.74%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):